31 July 2021 : Clinical Research
Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy
Xingqin Zhou1BCE, Yazhou Chang2BD, Jing Qian1BF, Chaoyan Shen1DEF, Jie Han1EF, Hongyu Zhao1DF, Renan Chang3AG*DOI: 10.12659/MSM.929474
Med Sci Monit 2021; 27:e929474
Figure 1 Distribution of measured 5-FU exposure (AUC) in every cycle of the Study Group. The AUC mean of the third cycle was significantly increased compared to the one at the first cycle (P=0.006).